Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Benjamin L. Wright is active.

Publication


Featured researches published by Benjamin L. Wright.


The Journal of Allergy and Clinical Immunology | 2017

Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective

Brian P. Vickery; Jelena P. Berglund; Caitlin M. Burk; Jason P. Fine; Edwin H. Kim; Jung In Kim; Corinne A. Keet; Michael D. Kulis; Kelly G. Orgel; Rishu Guo; Pamela H. Steele; Yamini Virkud; Ping Ye; Benjamin L. Wright; Robert A. Wood; A. Wesley Burks

Background: Oral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment. Objective: We sought to test the safety, effectiveness, and feasibility of early OIT (E‐OIT) in the treatment of peanut allergy. Methods: We enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy. Qualifying subjects reacted to peanut during an entry food challenge and were block‐randomized 1:1 to receive E‐OIT at goal maintenance doses of 300 or 3000 mg/d in a double‐blinded fashion. The primary end point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4‐SU), was assessed by double‐blinded, placebo‐controlled food challenge either upon achieving 4 prespecified criteria, or after 3 maintenance years. Peanut‐specific immune responses were serially analyzed. Outcomes were compared with 154 matched standard‐care controls. Results: Of 40 consented subjects, 3 (7.5%) did not qualify. Overall, 29 of 37 (78%) in the intent‐to‐treat analysis achieved 4‐SU (300‐mg arm, 17 of 20 [85%]; 3000 mg, 12 of 17 [71%], P = .43) over a median of 29 months. Per‐protocol, the overall proportion achieving 4‐SU was 29 of 32 (91%). Peanut‐specific IgE levels significantly declined in E‐OIT‐treated children, who were 19 times more likely to successfully consume dietary peanut than matched standard‐care controls, in whom peanut‐specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7‐43.7; P < .001). Allergic side effects during E‐OIT were common but all were mild to moderate. Conclusions: At both doses tested, E‐OIT had an acceptable safety profile and was highly successful in rapidly suppressing allergic immune responses and achieving safe dietary reintroduction.


Pediatric Clinics of North America | 2015

Current Options for the Treatment of Food Allergy

Bruce J. Lanser; Benjamin L. Wright; Kelly Orgel; Brian P. Vickery; David M. Fleischer

Food allergy is increasing in prevalence; as a result, there is intense focus on developing safe and effective therapies. Current methods of specific immunotherapy include oral, sublingual, and epicutaneous, while nonspecific methods that have been investigated include: Chinese herbal medicine, probiotics, and anti-IgE antibodies. Although some studies have demonstrated efficacy in inducing desensitization, questions regarding safety and the potential for achieving immune tolerance remain. Although some of these therapies demonstrate promise, further investigation is required before their incorporation into routine clinical practice.


Journal of the Pediatric Infectious Diseases Society | 2018

Infectious Complications in Patients With Chronic Granulomatous Disease

Nicholas Bennett; Paul J. Maglione; Benjamin L. Wright; Christa S. Zerbe


The Journal of Allergy and Clinical Immunology: In Practice | 2017

Throat-derived eosinophil peroxidase is not a reliable biomarker of pediatric eosinophilic esophagitis

Shauna Schroeder; Sergei I. Ochkur; Kelly P. Shim; Katie M. Galvin; Cindy S. Bauer; James J. Lee; Benjamin L. Wright


The Journal of Allergy and Clinical Immunology: In Practice | 2018

Adults Who Present for Evaluation of Multiple Food Allergies

Benjamin L. Wright; Matthew A. Rank


The Journal of Allergy and Clinical Immunology | 2018

Esophageal IgG4 and Eosinophilic Inflammation Correlate in Subjects Undergoing Peanut Oral Immunotherapy

Benjamin L. Wright; Matthew A. Rank; Kelly S. Shim; Alfred D. Doyle; Elizabeth A. Jacobsen; Monali Manohar; Bryan J. Bunning; R. Sharon Chinthrajah; Wenming Zhang; Kari C. Nadeau


The Journal of Allergy and Clinical Immunology | 2018

Failure to Consider Atopic Status Limits Existing Minimally-Invasive Biomarker Studies in Eosinophilic Esophagitis: A Systematic Review

Brittany T. Hines; Matthew A. Rank; Benjamin L. Wright; Lisa Marks; Matthew Greenhawt; Evan S. Dellon


The Journal of Allergy and Clinical Immunology | 2018

Increased GATA-3 and T-bet expression in eosinophilic esophagitis versus gastroesophageal reflux disease

Benjamin L. Wright; Nathalie Nguyen; Kelly P. Shim; Joanne C. Masterson; Elizabeth A. Jacobsen; Sergei I. Ochkur; James J. Lee; Glenn T. Furuta


The AAAAI/WAO Joint Congress | 2018

Eosinophilic Esophagitis and Eosinophilic Diseases

Benjamin L. Wright


The Journal of Allergy and Clinical Immunology | 2017

Difficulty Finding NEMO: Functional Pathways to Sequencing

Tyler R. Yates; Benjamin L. Wright; Cindy S. Bauer

Collaboration


Dive into the Benjamin L. Wright's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kelly P. Shim

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brian P. Vickery

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Cindy S. Bauer

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Evan S. Dellon

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

A. Wesley Burks

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge